Answers are grounded in this paper and cite their sources.
Increasing evidence supports a beneficial role of gut microbiota-derived metabolites in the treatment of non-small cell lung cancer (NSCLC). However, the contribution of gut microbial metabolites to the pathogenesis of NSCLC remains insufficiently explored. Data were obtained from the TCGA, GEO and gutMgene databases. Differentially expressed genes (DEGs) were analyzed using volcano and Venn diagrams. Analyses of gene ontology, kyoto encyclopedia of genes and genomes, and protein-protein interaction were performed to identify key pathways and targets. Microbiota-metabolites-targets-signaling (MMTS) pathway network was structured. Molecular docking was employed to evaluate binding affinity. Immune infiltration and single-cell transcriptomic analyses were additionally performed to characterize the cellular sources of the hub genes within the tumor microenvironment. 7 core targets were identified at the intersection of NSCLC-associated DEGs and gut metabolite-related targets. Functional enrichment analysis highlighted the interleukin (IL)-17 signaling pathway, tumor necrosis factor signaling pathway, lipid and atherosclerosis pathway, rheumatoid arthritis pathway, and advanced glycation end products-receptor signaling pathway in diabetic complications as key pathways involved in NSCLC progression. Fos proto-oncogene, AP-1 transcription factor subunit (FOS), IL-6 and C-C motif chemokine ligand 2 (CCL2) were suggested as pivotal genes. MMTS network linked 7 key metabolites (succinate, trimethylamine oxide, propionate, acetate, 3-indolepropionic acid, butyrate, and 10-keto-12Z-octadecenoic acid) to 6 gene targets. 3-indolepropionic acid was computationally predicted to have modest binding affinities with FOS (-6.3 kcal/mol), IL-6 (-5.9 kcal/mol), and CCL2 (-5.3 kcal/mol). Immune infiltration and single-cell analyses revealed that FOS, IL6, and CCL2 were predominantly expressed in myeloid and stromal compartments. This study predicts potential associations between gut microbial metabolites and NSCLC-related inflammatory genes, with 3-indolepropionic acid emerging as a candidate metabolite for future experimental validation. The computational findings suggest that 3-indolepropionic acid may directly interact with FOS, IL-6, and CCL2, providing a theoretical basis and a novel metabolite-target hypothesis for further mechanistic investigation of NSCLC regulation via the gut-lung axis. Immune infiltration and single-cell data indicate that FOS, IL6, and CCL2 are primarily derived from myeloid and stromal cells, providing cellular context for their roles in mediating gut microbiota effects on the NSCLC tumor microenvironment.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: